Hepatotoxicity due to drugs and other xenobiotics, also known as drug-induced liver injury (DILI), is a primary reason for 1) the termination of drug development programs, 2) the delay of approving otherwise efficacious drugs by requiring large and expensive safety-focused clinical trials, 3) the restriction on the clinical use of approved drugs by the inclusion of black box warnings, and 4) the removal of approved drugs from the market.
De-risking clinical hepatotoxicity early in the drug development process has never been possible—until now.
In this webinar, attendees learn how to use the only available software equipped to make clinically relevant liver safety predictions, permissive for early and later-stage drug discovery applications, involving multiple DILI mechanisms: oxidative stress, mitochondrial dysfunction, and inhibition of bile acid and phospholipid transporters.
Presenters describe a workflow utilizing several software tools—offered in a single package—to determine the hepatotoxic rankings of compounds as early as the discovery phase. Attendees see the case studies, demonstrating lower relative clinical hepatotoxic risk of compounds vs other in-class compounds.
Watch now to learn how you can optimize your early phase drug candidates for liver safety.
Presenters:
- Dr. Michael Lawless, Senior Principal Scientist, Cheminformatics Solutions
- Dr. Lisl Shoda, Associate Vice President and Director of Immunology, Quantitative Systems Pharmacology
- Dr. James Beaudoin, Senior Scientist, Quantitative Systems Pharmacology – Dr. Christina Battista, Principal Scientist, Quantitative Systems Pharmacology